Medanta-The Medicity has installed the Varian Edge radiation therapy system, marking a significant upgrade to its cancer treatment capabilities. The Varian Edge platform represents one of the most advanced radiotherapy technologies available, combining high-resolution imaging, precise dose delivery and adaptive planning tools to support personalised radiation therapy.

The system’s cutting-edge features include real-time tumour tracking, sub-millimetre treatment accuracy and automated motion management, which collectively enable clinicians to precisely deliver therapeutic doses while minimising exposure to surrounding healthy organs. These capabilities are especially valuable in treating tumours located near critical structures or those subject to movement, such as in lung, liver or pancreatic cancers.

According to Medanta’s oncology leadership, the Varian Edge system enhances clinical flexibility by allowing hypofractionated treatment regimens  where higher radiation doses are delivered in fewer sessions  potentially reducing patient visits and enhancing convenience without compromising efficacy. The platform’s adaptive planning tools allow for on-the-fly adjustments based on the tumour’s shape, size or position during the course of therapy.

Installation of this system aligns with Medanta’s strategy to integrate advanced technology into comprehensive cancer care, complementing surgical, medical oncology and supportive care services under one roof. By expanding its radiotherapy arsenal, the hospital aims to offer patients access to precision-focused treatment options comparable with leading global cancer centres.

Clinicians highlight that technologies like the Varian Edge system not only improve clinical precision but also enhance patient experience by offering shorter treatment times, fewer side effects and more predictable outcomes  critical factors in holistic oncology care.

Medanta’s investment underscores the ongoing evolution of cancer treatment in India, where high-end radiotherapy tools are increasingly integrated into standard care pathways to expand access to modern, evidence-based cancer therapies.